BMSN. FDA FILING HemaXellerate™ [Regen intends to file an Investigational New Drug (IND) Application in the fourth quarter of 2012 ] patent No. 6,821,513 prweb/releases/2012/10/prweb9972993.htm HemaXellerate™ offers the possibility of delivering a population of endothelial cells to restore blood production in patients with hematological conditions. "Unlike current approaches of administering pharmaceuticals," said J. Christopher Mizer, President of Regen BioPharma, "our strategy is to heal the bone marrow by administering cells that provide the optimum mix of growth factors to stimulate the bone marrow into producing blood cells naturally." Regen has submitted two provisional patent applications covering the use of different sources of endothelial cells to heal damaged bone marrow. These applications cover: (1) placental cells (61/648898 - Acceleration 0f Hematopoietic Reconstitution by Placental Endothelial and Endothelial Progenitor Cells); and (2) fat cells (61/670791 - Treatment of Hematopoietic Disorders). White Papers: Journal of Translation Medicine translational-medicine/content/pdf/1479-5876-10-231.pdf
Posted on: Thu, 15 Aug 2013 02:24:05 +0000
Trending Topics
© 2015